The European Medicines Agency accepted the marketing authorization application for avacincaptad pegol, according to a press release from Astellas Pharma.
Avacincaptad pegol is a complement C5 inhibitor under investigation in the EU for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration.
The EMA’s Committee for Medicinal Products for Human Use (CHMP) will review the application under the centralized licensing procedure for the 27 member states of the European Union.
“This acceptance of our EU marketing authorization application is a key milestone in